Boston Scientific (BSX) Non-Current Debt (2009 - 2026)

Boston Scientific (BSX) has 18 years of Non-Current Debt data on file, last reported at $11.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 4.33% year-over-year to $11.0 billion; the trailing twelve-month figure through Mar 2026 stood at $11.0 billion (up 4.33% YoY), and the FY2025 full-year result was $11.1 billion, up 24.19% from the prior year.
• Non-Current Debt declined to $11.0 billion in Q1 2026, from $11.1 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $11.1 billion in Q4 2025 to a low of $500.0 million in Q2 2025.
• A 5-year average of $8.2 billion and a median of $8.8 billion in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt surged 161.71% in 2023 and sank 94.44% in 2025, its largest moves.
• Tracing BSX's Non-Current Debt over 5 years: stood at $3.3 billion in 2022, then surged by 161.71% to $8.6 billion in 2023, then climbed by 4.63% to $9.0 billion in 2024, then rose by 24.19% to $11.1 billion in 2025, then decreased by 1.34% to $11.0 billion in 2026.
• Business Quant data shows BSX's Non-Current Debt at $11.0 billion in Q1 2026, $11.1 billion in Q4 2025, and $11.1 billion in Q3 2025.